Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

CRL

HoldHot AirFLAG

Charles River Laboratories International, Inc. · Healthcare · United States · $14.0B · Avg Vol: $247M/d

63
StockRank
Get insider-trade alerts
Q
45
V
34
M
79
P/E (TTM)
ROE
-7.5%
D/E
1.1x
Dividend %
AI CONVICTION THESIS

Insufficient evidence for a screen-pass. Charles River Laboratories International, Inc.: fails the quant gate on quality, value (Q45/V34/M79; every leg must be >= 50). Absence of evidence is neutral; nothing adverse is known.

COMPANY DESCRIPTION

Charles River Laboratories International, Inc. is a leading global contract research organization (CRO), providing a comprehensive suite of preclinical and clinical laboratory services to pharmaceutical, biotechnology, government, and academic clients. The company's competitive moat stems from its integrated service offerings, specialized scientific expertise, global operational scale, and the high switching costs for its clients in critical drug development phases. It serves as an indispensable partner in early-stage drug discovery and development.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue4.0B4.1B4.0B4.0B0.3%4.0B3.9B4.0B-0.2%
EPS9.579.270.20-2.91-85.5%-4.81
Shares50.9M51.3M51.1M49.2M-3.4%48.2M
Debt3.1B3.1B2.7B2.6B-6.0%3.0B
Equity3.0B3.6B3.5B3.2B2.1%
Op CF619.6M683.9M734.6M737.6M6.0%582.1M
Inv CF-607.9M-563.2M-245.1M-209.3M
Fin CF-42.4M-85.5M-550.9M-536.7M
Loading 1Y...
PRICE (1Y)+16.4%
231248265282299Jul 30Aug 20Sep 10
SMA 50SMA 200

Close
$273.00
RSI (14)
33.9
52W High
$303.31
From 52W High
0.9%

SCORE BREAKDOWN

Quality
45
ROIC
-1.3%42.8
ROE
-7.5%37.2
GP/Assets
19.4%43.6
Op. Margin
15.1%74.9
FCF/Assets
5.2%70.9
Piotroski
549.1
Int. Cover
-0.7x34.5
D/E Ratio
1.05x13.2
Current Ratio
1.35x21.6
Value
34
P/E (TTM)
N/A
EV/EBITDA
19.9x34.6
P/FCF
37.9x39.1
P/B
4.8x29.6
P/S
3.5x52.3
Div Yield
N/A
Momentum
79
52W High %
90%87.0
RS 6M
49%91.1
SMA 50/200
1.28x92.4
EPS Rev 4W
+2.9%72.8
EPS Rev 12W
+3.1%74.6
EPS Improve
+364%93.7
Q Growth
N/A

FUNDAMENTALS

Market Cap
$14.0B
P/E (Forward)
22.7x
Gross Margin
34.6%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CRL are excluded.

TickerCompanyMkt CapStockRankSignal
CRLCharles River Laboratories International, Inc.(you)$14.0B63Hold
RVTYRevvity, Inc.$14.4B64Hold
MEDPMedpace Holdings, Inc.$16.8B80Strong Buy
WATWaters Corporation$40.7B62Hold
TWSTTwist Bioscience Corporation$8.9B47Hold
BLLNBillionToOne, Inc.$4.4B61Hold
IDXXIDEXX Laboratories, Inc.$43.7B58Hold
ILMNIllumina, Inc.$32.6B75Buy
GHGuardant Health, Inc.$21.7B42Hold
NTRANatera, Inc.$47.0B56Hold

Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.3%

Charles River Laboratories International, Inc. (CRL): Stock Score Summary

Charles River Laboratories International, Inc. (CRL) has a MoatMap StockRank of 63/100 based on Quality (45/100), Value (34/100), and Momentum (79/100) factor scores. The current signal is HOLD. Insufficient evidence for a screen-pass. Charles River Laboratories International, Inc.: fails the quant gate on quality, value (Q45/V34/M79; every leg must be >= 50). Absence of evidence is neutral; nothing adverse is known.

Charles River Laboratories International, Inc. is a leading global contract research organization (CRO), providing a comprehensive suite of preclinical and clinical laboratory services to pharmaceutical, biotechnology, government, and academic clients. The company's competitive moat stems from its integrated service offerings, specialized scientific expertise, global operational scale, and the high switching costs for its clients in critical drug development phases. It serves as an indispensable partner in early-stage drug discovery and development.

Key Financial Metrics

Price$273.00
Market Cap$14.0B
P/E (Forward)22.74
Price/Book4.85
Return on Equity-7.5%
Return on Invested Capital-1.3%
Debt/Equity1.05x
Gross Margin34.6%
Operating Margin15.1%
Revenue Growth-2.7%
Free Cash Flow$371M

Charles River Laboratories International, Inc. operates in the Diagnostics & Research industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Charles River Laboratories International, Inc.’s (CRL) StockRank?
MoatMap’s StockRank for Charles River Laboratories International, Inc. (CRL) is 63/100, with a Hold signal. It is a composite of Quality (45), Value (34), and Momentum (79) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Charles River Laboratories International, Inc. have an economic moat?
Charles River Laboratories International, Inc. (CRL) has a Quality factor score of 45/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Charles River Laboratories International, Inc. a buy, hold, or sell?
MoatMap’s current signal for Charles River Laboratories International, Inc. (CRL) is Hold, based on a StockRank of 63/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Charles River Laboratories International, Inc. in?
Charles River Laboratories International, Inc. (CRL) operates in the Healthcare sector, specifically the Diagnostics & Research industry (United States).